By Caitlin Dolegowski, Program Director, LSN
Every January, tens of thousands of healthcare executives head to San Francisco for J.P. Morgan Healthcare Week. The conventional advice given to founders is simple: “You have to be there.”
So founders book non-refundable flights, secure hotel rooms topping $1,000 a night, and arrive with high hopes. Within 48 hours, reality sets in:
- The Calendar Lockout: Institutional venture capital funds and big pharma search and evaluation teams do not leave schedules open for casual run-ins. Their diaries are locked down weeks before the conference begins.
- The “Lobby Chasing” Trap: Founders end up pitching sensitive science in crowded hotel lobbies, shouting over espresso machines and cold-messaging investors on LinkedIn with little to no response.
- The Stage Mismatch: The official, invitation-only JPM conference is built primarily for public companies, late-stage clinical assets, and large institutional asset allocators. If you are raising Seed, Series A, or Series B, the main conference is not built for your deal size.
The hard part of early-stage fundraising during JPM Week is not the pitch. It is qualified access.
To turn JPM Week into a strategic milestone rather than an expensive distraction, early-stage innovators need a dedicated, mandate-driven partnering ecosystem.
Why RESI JPM Is the Premier Partnering Anchor for Emerging Life Science
Held in person on January 11 and 12 at the San Francisco Marriott Marquis, followed by three virtual partnering days on January 13, 18, and 19, RESI JPM (Redefining Early Stage Investments) was engineered specifically to solve the structural challenges early-stage companies face.
- Buy-Side Density Over Vanity Numbers
Unlike conventions that inflate attendance with service vendors and non-investors, RESI focuses on buy-side capital. The conference convenes over 850 active capital allocators—including venture funds, corporate venture capital (CVC) arms, family offices, and pharma business development scouts actively seeking Seed to Series B assets across therapeutics, medical devices, diagnostics, and digital health.
- Mandate-Specific 1-on-1 Partnering
RESI’s proprietary partnering system eliminates guesswork. Founders can filter the entire investor directory by therapeutic indication, modality, development stage, and check size before arriving in San Francisco. Meetings are confirmed in advance and held at reserved, numbered tables inside the Yerba Buena Ballroom, saving hours of transit.
- The 5-Day Hybrid Advantage
JPM moves at breakneck speed. By combining two intensive in-person days (Jan 11–12) with three dedicated virtual partnering days (Jan 13, 18, and 19), founders can conduct immediate follow-ups with local investors and access a massive cohort of international and cross-border funds participating remotely.
- The Innovator’s Pitch Challenge (IPC)
Startups seeking elevated visibility can apply to pitch live in front of active investor panels. Finalists receive dedicated exhibition poster space on the main floor and direct, scored evaluation feedback sheets from judges following the session.
Three Rules to Make Your JPM Week Count
- Stop Relying on Serendipity: Hoping to meet the right investor in a hotel lobby is not a fundraising strategy. High-yield JPM deals are born from targeted meetings booked in advance through formal partnering platforms.
- Anchor Your Geography: Crossing San Francisco between Union Square and Mission Bay can eat up an hour. Establish your base camp at an established hub like RESI inside the Marriott Marquis to eliminate transit friction.
- Diversify Your Capital Sources: Look beyond traditional venture funds. Tap into family offices, foundation endowments, and strategic corporate partners who are actively seeking early-stage co-investments.
Explore the RESI JPM 2027 partnering platform, review confirmed investors, and register today at RESIConference.com or contact resi@lifesciencenation.com.
| Register for RESI JPM 2027 |
